GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » 5-Year Yield-on-Cost %

Cadence Pharmaceuticals, (FRA:QEW) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, 5-Year Yield-on-Cost %?

Cadence Pharmaceuticals,'s yield on cost for the quarter that ended in Dec. 2013 was 0.00.


The historical rank and industry rank for Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:QEW's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost % falls into.



Cadence Pharmaceuticals, 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cadence Pharmaceuticals, is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Cadence Pharmaceuticals,  (FRA:QEW) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cadence Pharmaceuticals, 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines